Zhejiang Boxiao Biopharmaceutical Co., Ltd.

Primary objective: To evaluate the effectiveness of methylergonovine maleate injection in preventing postpartum hemorrhage. Secondary objective: To evaluate the safety of methylergonovine maleate injection in preventing postpartum hemorrhage.

Primary objective: To compare the differences in the extent and rate of absorption of bupivacaine liposome injection (specification: 266 mg/20 mL) provided by Zhejiang Boqiao Biopharmaceutical Co., Ltd. and bupivacaine liposome injection (specification: 266 mg/20 mL, trade name: Exparel®) certified by Pacira Phrumaceuticals Inc. in healthy adults under fasting conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of bupivacaine liposome injection (specification: 266 mg/20 mL) provided by Zhejiang Boqiao Biopharmaceutical Co., Ltd. under fasting conditions.

Primary objective: To determine the drug concentrations at different times after a single intravenous and intramuscular injection of methylergonovine maleate injection in healthy female subjects and to evaluate its pharmacokinetic characteristics. Secondary objective: To evaluate the safety and tolerability of a single intravenous and intramuscular injection of methylergonovine maleate injection in healthy female subjects.